Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CTMX CytomX Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: CTMX
Price (delayed)
$2.36
Market cap
$190.27M
P/E Ratio
4.82
Dividend/share
N/A
EPS
$0.49
Enterprise value
$149.78M
CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. CytomX is developing a novel class of investigational conditionally activated antibody therapeutics,
Highlights
CTMX's equity has surged by 179% year-on-year
CytomX Therapeutics's net income has surged by 152% YoY and by 31% QoQ
Key stats
What are the main financial stats of CTMX
Market
Valuations
Earnings
Shares outstanding
80.62M
Market cap
$190.27M
Enterprise value
$149.78M
Price to earnings (P/E)
4.82
Price to book (P/B)
7.55
Price to sales (P/S)
1.39
EV/EBIT
3.58
EV/EBITDA
3.14
EV/Sales
1.02
Revenue
$147.56M
Gross profit
$147.56M
Operating income
$35.96M
Net income
$41.6M
EBIT
$41.84M
EBITDA
$47.7M
Free cash flow
-$81.54M
Per share
Balance sheet
Liquidity
EPS
$0.49
EPS diluted
$0.49
Free cash flow per share
-$0.94
Book value per share
$0.31
Revenue per share
$1.69
TBVPS
$1.11
Total assets
$98.5M
Total liabilities
$73.45M
Debt
$8.15M
Equity
$25.05M
Working capital
$36.43M
Debt to equity
0.33
Current ratio
1.73
Quick ratio
1.65
Net debt/EBITDA
-0.85
Margins
Efficiency
Dividend
EBITDA margin
32.3%
Gross margin
100%
Net margin
28.2%
Operating margin
24.4%
Return on assets
32.2%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
86.6%
Return on sales
28.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CTMX stock price
How has the CytomX Therapeutics stock price performed over time
Intraday
3.96%
1 week
10.28%
1 month
-10.94%
1 year
77.44%
YTD
129.13%
QTD
3.96%
Financial performance
How have CytomX Therapeutics's revenue and profit performed over time
Revenue
$147.56M
Gross profit
$147.56M
Operating income
$35.96M
Net income
$41.6M
Gross margin
100%
Net margin
28.2%
The company's operating margin has surged by 168% YoY and by 35% QoQ
CytomX Therapeutics's net income has surged by 152% YoY and by 31% QoQ
CTMX's net margin has surged by 103% year-on-year and by 22% since the previous quarter
The operating income is up by 44% since the previous quarter
Price vs fundamentals
How does CTMX's price correlate with its fundamentals
Growth
What is CytomX Therapeutics's growth rate over time
Valuation
What is CytomX Therapeutics stock price valuation
P/E
4.82
P/B
7.55
P/S
1.39
EV/EBIT
3.58
EV/EBITDA
3.14
EV/Sales
1.02
The EPS has soared by 145% YoY and by 29% from the previous quarter
CTMX's P/E is 6% lower than its last 4 quarters average of 4.9
CTMX's equity has surged by 179% year-on-year
The stock's P/S is 91% more than its last 4 quarters average of 0.7 but 67% less than its 5-year quarterly average of 4.1
CTMX's revenue is up by 24% year-on-year and by 7% since the previous quarter
Efficiency
How efficient is CytomX Therapeutics business performance
The ROS has soared by 65% YoY and by 22% from the previous quarter
CTMX's return on assets has surged by 53% since the previous quarter
Dividends
What is CTMX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CTMX.
Financial health
How did CytomX Therapeutics financials performed over time
CTMX's total assets is 34% more than its total liabilities
The company's total liabilities has shrunk by 66% YoY and by 39% QoQ
The company's current ratio rose by 49% YoY and by 38% QoQ
CTMX's debt is 67% smaller than its equity
The debt to equity has soared by 180% year-on-year and by 102% since the previous quarter
CTMX's equity has surged by 179% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.